These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15056640)

  • 21. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin.
    Leclercq R
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():9-23. PubMed ID: 11566972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of the new ketolide ABT-773 against community acquired respiratory tract isolates and Viridans Streptococci.
    Casellas JM; Tomé G; Visser M; Gliosca L
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):107-12. PubMed ID: 11858905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative antimicrobial activity of the new macrolide flurithromycin against respiratory pathogens.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):71-3. PubMed ID: 3132384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Killing rate and growth rate comparison for newer beta-lactamase-stable oral beta-lactams against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1992; 38(1):7-13. PubMed ID: 1618006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens.
    Cizman M; Pokorn M; Seme K; Orazem A; Paragi M
    J Antimicrob Chemother; 2001 Apr; 47(4):475-7. PubMed ID: 11266425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
    McGhee P; Clark C; Kosowska-Shick KM; Nagai K; Dewasse B; Beachel L; Appelbaum PC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):230-8. PubMed ID: 19884376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.
    Jorgensen JH; Doern GV; Maher LA; Howell AW; Redding JS
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2075-80. PubMed ID: 2127342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK.
    Johnson AP; Henwood CJ; Tysall L; Warner M
    Int J Antimicrob Agents; 2001 Jul; 18(1):73-6. PubMed ID: 11463530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.
    Thornsberry C; Ogilvie PT; Holley HP; Sahm DF
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2612-23. PubMed ID: 10543737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.
    Yamada T; Yokota Y; Ikeda F; Mine Y; Kitada T
    Chemotherapy; 1992; 38(1):28-35. PubMed ID: 1618001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics.
    Bonnefoy A; Le Priol P
    J Antimicrob Chemother; 2001 Apr; 47(4):471-3. PubMed ID: 11266424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries.
    Bandak SI; Turnak MR; Allen BS; Bolzon LD; Preston DA; Bouchillon SK; Hoban DJ
    Eur J Clin Microbiol Infect Dis; 2001 Jan; 20(1):55-60. PubMed ID: 11245326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Critchley IA; Karlowsky JA; Draghi DC; Jones ME; Thornsberry C; Murfitt K; Sahm DF
    Antimicrob Agents Chemother; 2002 Feb; 46(2):550-5. PubMed ID: 11796376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of amoxycillin/clavulanic acid and five other oral antibiotics against clinical isolates of Haemophilus influenzae and Branhamella catarrhalis.
    Fernández-Roblas R; Jiménez Arriero M; Rodriguez-Tudela JL; Soriano F
    J Antimicrob Chemother; 1988 Dec; 22(6):867-72. PubMed ID: 3149634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic susceptibility of upper respiratory tract pathogens in Sweden: a seven year follow-up study including loracarbef. Swedish Respiratory Tract Study Group.
    Olsson-Liljequist B; Burman LG; Kallings I
    Scand J Infect Dis; 1992; 24(4):485-93. PubMed ID: 1411315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.
    Rospide MF; Biedenbach DJ; Jones RN
    Int J Antimicrob Agents; 2001 Jun; 17(6):451-5. PubMed ID: 11397614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium.
    Verhaegen J; Verbist L
    Acta Clin Belg; 2001; 56(6):349-53. PubMed ID: 11881319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland.
    Betlejewska K; Hryniewicz W
    Int J Antimicrob Agents; 2002 Jan; 19(1):47-52. PubMed ID: 11814767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the resistance patterns among upper respiratory tract infection pathogens.
    Stefani S
    Int J Antimicrob Agents; 2000 Dec; 16(4):493-4. PubMed ID: 11118865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.